Open AccessTocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
Author(s) -
Prashant Nasa,
Aanchal Singh,
Surjya Prasad Upadhyay,
Sukhant Bagadia,
Srinivasa Polumuru,
Pavan Kumar Shrivastava,
Rakesh Sankar,
Lexy Vijayan,
Mohamed A. Soliman,
Alaeldin Ali,
Saroj Patidar
Publication year - 2020
Publication title -
indian journal of critical care medicine/indian journal of critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 30
eISSN - 1998-359X
pISSN - 0972-5229
DOI - 10.5005/jp-journals-10071-23566
Subject(s) - tocilizumab , medicine , cytokine release syndrome , retrospective cohort study , interleukin 6 , adverse effect , mechanical ventilation , covid-19 , cytokine , disease , infectious disease (medical specialty)
Cytokine-release syndrome (CRS) in COVID-19 patients can cause multiorgan failure and higher mortality. We used a structured protocol based on clinical, biochemical, and interleukin 6 (IL-6) criteria for the identification of the subset of patients with CRS and analyzed the use of tocilizumab for their treatment.